279 related articles for article (PubMed ID: 35405339)
1. Inflammation targeted nanomedicines: Patents and applications in cancer therapy.
Praveen TK; Gangadharappa HV; Abu Lila AS; Moin A; Mehmood K; Krishna KL; Hussain T; Alafnan A; Shakil S; Rizvi SMD
Semin Cancer Biol; 2022 Nov; 86(Pt 2):645-663. PubMed ID: 35405339
[TBL] [Abstract][Full Text] [Related]
2. Organoids technology for advancing the clinical translation of cancer nanomedicine.
Zhao DK; Liang J; Huang XY; Shen S; Wang J
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(5):e1892. PubMed ID: 37088100
[TBL] [Abstract][Full Text] [Related]
3. Artificial intelligence aids in development of nanomedicines for cancer management.
Tan P; Chen X; Zhang H; Wei Q; Luo K
Semin Cancer Biol; 2023 Feb; 89():61-75. PubMed ID: 36682438
[TBL] [Abstract][Full Text] [Related]
4. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
Patel P; Shah J
Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
[TBL] [Abstract][Full Text] [Related]
5. Progress and challenges in the translation of cancer nanomedicines.
Tong F; Wang Y; Gao H
Curr Opin Biotechnol; 2024 Feb; 85():103045. PubMed ID: 38096768
[TBL] [Abstract][Full Text] [Related]
6. Current nano-therapeutic approaches ameliorating inflammation in cancer progression.
Rehman MU; Khan A; Imtiyaz Z; Ali S; Makeen HA; Rashid S; Arafah A
Semin Cancer Biol; 2022 Nov; 86(Pt 2):886-908. PubMed ID: 35143992
[TBL] [Abstract][Full Text] [Related]
7. Antibody-Incorporated Nanomedicines for Cancer Therapy.
Wu SY; Wu FG; Chen X
Adv Mater; 2022 Jun; 34(24):e2109210. PubMed ID: 35142395
[TBL] [Abstract][Full Text] [Related]
8. Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines.
Balasubramanian V; Liu Z; Hirvonen J; Santos HA
Adv Healthc Mater; 2018 Jan; 7(1):. PubMed ID: 28570787
[TBL] [Abstract][Full Text] [Related]
9. Cancer nanomedicine toward clinical translation: Obstacles, opportunities, and future prospects.
Zhang P; Xiao Y; Sun X; Lin X; Koo S; Yaremenko AV; Qin D; Kong N; Farokhzad OC; Tao W
Med; 2023 Mar; 4(3):147-167. PubMed ID: 36549297
[TBL] [Abstract][Full Text] [Related]
10. Multi-functionalization, a Promising Adaptation to Overcome Challenges to Clinical Translation of Nanomedicines as Nano-diagnostics and Nano-therapeutics for Breast Cancer.
Moti LAA; Hussain Z; Thu HE; Khan S; Sohail M; Sarfraz RM
Curr Pharm Des; 2021; 27(43):4356-4375. PubMed ID: 34459374
[TBL] [Abstract][Full Text] [Related]
11. Progress of Cancer Nanotechnology as Diagnostics, Therapeutics, and Theranostics Nanomedicine: Preclinical Promise and Translational Challenges.
Alshehri S; Imam SS; Rizwanullah M; Akhter S; Mahdi W; Kazi M; Ahmad J
Pharmaceutics; 2020 Dec; 13(1):. PubMed ID: 33374391
[TBL] [Abstract][Full Text] [Related]
12. Nanomedicines: intervention in inflammatory pathways of cancer.
Anwar F; Naqvi S; Shams S; Sheikh RA; Al-Abbasi FA; Asseri AH; Baig MR; Kumar V
Inflammopharmacology; 2023 Jun; 31(3):1199-1221. PubMed ID: 37060398
[TBL] [Abstract][Full Text] [Related]
13. Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives.
Ali ES; Sharker SM; Islam MT; Khan IN; Shaw S; Rahman MA; Uddin SJ; Shill MC; Rehman S; Das N; Ahmad S; Shilpi JA; Tripathi S; Mishra SK; Mubarak MS
Semin Cancer Biol; 2021 Feb; 69():52-68. PubMed ID: 32014609
[TBL] [Abstract][Full Text] [Related]
14. Nanomedicines as cancer therapeutics: current status.
Akhter S; Ahmad I; Ahmad MZ; Ramazani F; Singh A; Rahman Z; Ahmad FJ; Storm G; Kok RJ
Curr Cancer Drug Targets; 2013 May; 13(4):362-78. PubMed ID: 23517593
[TBL] [Abstract][Full Text] [Related]
15. Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation.
Gu W; Meng F; Haag R; Zhong Z
J Control Release; 2021 Jan; 329():676-695. PubMed ID: 33022328
[TBL] [Abstract][Full Text] [Related]
16. Nanotechnology in inflammation: cutting-edge advances in diagnostics, therapeutics and theranostics.
Liu Y; Lin Z; Wang Y; Chen L; Wang Y; Luo C
Theranostics; 2024; 14(6):2490-2525. PubMed ID: 38646646
[TBL] [Abstract][Full Text] [Related]
17. Trends in Nanomedicines for Cancer Treatment.
do Nascimento T; Todeschini AR; Santos-Oliveira R; de Souza de Bustamante Monteiro MS; de Souza VT; Ricci-Júnior E
Curr Pharm Des; 2020; 26(29):3579-3600. PubMed ID: 32186271
[TBL] [Abstract][Full Text] [Related]
18. Polyprodrug Nanomedicines: An Emerging Paradigm for Cancer Therapy.
Yang K; Yang Z; Yu G; Nie Z; Wang R; Chen X
Adv Mater; 2022 Feb; 34(6):e2107434. PubMed ID: 34693571
[TBL] [Abstract][Full Text] [Related]
19. Carrier-Free Nanomedicine for Cancer Immunotherapy.
Fu Y; Bian X; Li P; Huang Y; Li C
J Biomed Nanotechnol; 2022 Apr; 18(4):939-956. PubMed ID: 35854464
[TBL] [Abstract][Full Text] [Related]
20. Herbal nanomedicines: Recent advancements, challenges, opportunities and regulatory overview.
Teja PK; Mithiya J; Kate AS; Bairwa K; Chauthe SK
Phytomedicine; 2022 Feb; 96():153890. PubMed ID: 35026510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
